Author: Gonzalez-Rubio, Jesus; Navarro-Lopez, Carmen; Lopez-Najera, Elena; Lopez-Najera, Ana; Jimenez-Diaz, Lydia; Navarro-Lopez, Juan D.; Najera, Alberto
Title: Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm Cord-id: i8y1kwul Document date: 2020_6_11
ID: i8y1kwul
Snippet: SARS-CoV-2 is a new coronavirus that has caused a worldwide pandemic. It causes severe acute respiratory syndrome (COVID-19), which is fatal in many cases, and is characterized by a cytokine release syndrome (CRS). Great efforts are currently being made to block the signal transduction pathway of pro-inflammatory cytokines in order to control this “cytokine storm†and rescue severely affected patients. Consequently, possible treatments for cytokine-mediated hyperinflammation, preferably with
Document: SARS-CoV-2 is a new coronavirus that has caused a worldwide pandemic. It causes severe acute respiratory syndrome (COVID-19), which is fatal in many cases, and is characterized by a cytokine release syndrome (CRS). Great efforts are currently being made to block the signal transduction pathway of pro-inflammatory cytokines in order to control this “cytokine storm†and rescue severely affected patients. Consequently, possible treatments for cytokine-mediated hyperinflammation, preferably within approved safe therapies, are urgently being researched to reduce rising mortality. One approach to inhibit proinflammatory cytokine release is to activate the cholinergic anti-inflammatory pathway through nicotinic acetylcholine receptors (α7nAchR). Nicotine, an exogenous α7nAchR agonist, is clinically used in ulcerative colitis to counteract inflammation. We have found epidemiological evidence, based on recent clinical SARS-CoV-2 studies in China, that suggest that smokers are statistically less likely to be hospitalized. In conclusion, our hypothesis proposes that nicotine could constitute a novel potential CRS therapy in severe SARS-CoV-2 patients.
Search related documents:
Co phrase search for related documents- acetylcholine receptor and acute respiratory infection: 1
- acetylcholine receptor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
- acetylcholine receptor and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5
- acetylcholine receptor and lung inflammatory: 1, 2, 3, 4, 5
- acetylcholine receptor and lung inflammatory response: 1, 2
- acetylcholine receptor and lung inflammatory response reduce: 1
- acetylcholine receptor and lung injury: 1, 2, 3, 4, 5, 6
- acute lung injury and administration route: 1, 2
- acute lung injury and lung hyperinflammation: 1, 2, 3
- acute lung injury and lung inflammatory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute lung injury and lung inflammatory response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute lung injury and lung inflammatory response reduce: 1
- acute lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory infection and additional report: 1, 2
- acute respiratory infection and administration route: 1, 2, 3, 4
- acute respiratory infection and lung hyperinflammation: 1, 2, 3
- acute respiratory infection and lung inflammatory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory infection and lung inflammatory response: 1, 2, 3, 4, 5
- acute respiratory infection and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date